Company Profile
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Latest News
Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight
Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?
Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)
KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback
Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| Website | https://www.kenvue.com |
| Audit Risk | 4 |
| Board Risk | 3 |
| Overall Risk | 5 |
| Market Cap | 37.02B |
| Trailing P/E | 22.95 |
| Forward P/E | 15.55 |
| Dividend Rate | 0.83 |
| Dividend Yield | 4.30% |
| Trailing Annual Div. Rate | 0.83 |
| Trailing Annual Div. Yield | 4.38% |
| Trailing EPS | 0.84 |
| Forward EPS | 1.24 |
| Book Value | 5.53 |
| Price-to-Book | 3.49 |
| Enterprise-to-Revenue | 2.93 |
| Enterprise-to-EBITDA | 12.9 |
| Short Ratio | 2.89 |
| Ex-Dividend Date | 05/13/2026 |
| Dividend Date | 05/27/2026 |
| Earnings Date | 08/06/2026 |
| Earnings Call Date | |
| Earnings Average | 0.32 |
| Earnings Low | 0.29 |
| Earnings High | 0.35 |
| Revenue Average | 3.97B |
| Revenue Low | 3.93B |
| Revenue High | 4.00B |